Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to treat renal carcinoma and differentiated thyroid carcinoma.
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
- Associated Therapies
- -
Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
- Conditions
- Interventions
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT02406521
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC)
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2018-01-16
- Lead Sponsor
- Yakult Honsha Co., LTD
- Target Recruit Count
- 179
- Registration Number
- NCT02400788
A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma
- First Posted Date
- 2015-02-09
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT02358395
- Locations
- 🇯🇵
4 Sites, Tokyo,etc, Japan
A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Sumitomo Pharma Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT02354898
- Locations
- 🇯🇵
5 Sites, Chiba, Etc., Japan
Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-01-29
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 23
- Registration Number
- NCT02349867
- Locations
- 🇺🇸
Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States
Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients
- First Posted Date
- 2015-01-05
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 106
- Registration Number
- NCT02330783
- Locations
- 🇨🇳
Sun Yat-sen university cancer center, Guangzhou, Guangdong, China
🇨🇳Peking University First Hospital, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, China
Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 12
- Registration Number
- NCT02323906
- Locations
- 🇺🇸
University of Florida College of Med, Gainesville, Florida, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study)
- Conditions
- Interventions
- First Posted Date
- 2014-12-08
- Last Posted Date
- 2017-12-18
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 55
- Registration Number
- NCT02311205
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2024-02-09
- Target Recruit Count
- 18
- Registration Number
- NCT02298348
- Locations
- 🇺🇸
Cook Children's Healthcare System, Fort Worth, Texas, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-11-17
- Last Posted Date
- 2021-06-10
- Target Recruit Count
- 17
- Registration Number
- NCT02292173
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.